Bachofen H, Im Hof V
Pneumologische Abteilung, Medizinische Universitätsklinik, Bern.
Ther Umsch. 1992 Oct;49(10):678-83.
Until recently, optimal bronchodilatation and in particular the inhalation of beta-agonists was considered the mainstay of asthma therapy. Steroids were added only in case of an unsatisfactory treatment effect. Recent epidemiological surveys, revealing an association between asthma mortality and the use of beta-agonists, and well controlled treatment studies suggest a change of concepts. Considering the long-term course of asthma, early suppression of asthmatic airway inflammation appears to be at least as important as an effective bronchodilatation. A prerequisite for a success of an individually taylored pharmacologic treatment is a comprehensive management of the disease, inclusive a continuous patient education.
直到最近，最佳支气管扩张，尤其是吸入β-激动剂一直被视为哮喘治疗的主要手段。仅在治疗效果不理想时才添加类固醇。最近的流行病学调查揭示了哮喘死亡率与β-激动剂使用之间的关联，且控制良好的治疗研究表明观念发生了变化。考虑到哮喘的长期病程，早期抑制哮喘气道炎症似乎至少与有效的支气管扩张同样重要。个体化药物治疗成功的一个先决条件是对该疾病进行全面管理，包括持续的患者教育。
